Gross Margin: A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. Calculated as: Gross Income / Total Revenues
C4 Therapeutics, Inc. (CCCC) had Gross Margin of 100.00% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$35.95M |
|
$-104.99M |
|
-- |
|
$35.95M |
|
$151.17M |
|
$-115.22M |
|
$10.35M |
|
$-104.87M |
|
$-104.87M |
|
$-104.99M |
|
$-104.99M |
|
$-104.99M |
|
$-104.99M |
|
$-115.22M |
|
$-116.00M |
|
82.89M |
|
82.89M |
|
$-1.27 |
|
$-1.27 |
|
| Balance Sheet Financials | |
$258.11M |
|
$4.74M |
|
$100.97M |
|
$359.07M |
|
$33.03M |
|
-- |
|
$69.46M |
|
$102.49M |
|
$256.59M |
|
$256.59M |
|
$256.59M |
|
96.91M |
|
| Cash Flow Statement Financials | |
$-98.69M |
|
$-8.60M |
|
$126.40M |
|
$58.94M |
|
$78.05M |
|
$19.10M |
|
$19.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.81 |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Gross Margin |
100.00% |
-320.53% |
|
-320.53% |
|
-322.71% |
|
-291.74% |
|
-292.08% |
|
$-99.30M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
14.97 |
|
24.38 |
|
-40.92% |
|
-40.92% |
|
-29.24% |
|
-40.92% |
|
$2.65 |
|
$-1.20 |
|
$-1.19 |
|